LeMaitre Q3 2026 Financial Results

The acquired B. Braun products are expected to contribute approximately $150,000 in fourth-quarter sales with break-even operating income impact.

Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) reported third-quarter 2026 sales of $68.0 million, up 11% from the same quarter last year. Organic growth was 12%, comprising 7% pricing and 5% unit growth. Gross margin fell to 71.7% from 75.3%, but rose from 70.8% excluding the prior-year employee retention tax credit. Operating income fell 13% to $17.7 million; diluted EPS was $0.65 versus $0.75.

In October, LeMaitre acquired vascular assets from B. Braun for $19.2 million. The products generated $9.4 million in 2025 sales outside North America; sales will transition into LeMaitre’s channel over 18–24 months. The company forecasts full-year sales of $274.8–$276.8 million and EPS of $2.77–$2.82, including the acquisition. Cash and short-term securities totaled approximately $390 million at September 30. A $0.25 quarterly dividend is payable December 3, 2026.

18 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointQ3 sales rose 11% to $68.0 million; organic growth was 12%, comprising 7% pricing and 5% units.
• Moderate pointB. Braun asset acquisition added products with $9.4 million in 2025 sales, all outside North America.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Q4 sales guidance is $69.9–$71.9 million, with midpoint growth of 10%, or 11% organically.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year sales guidance is $274.8–$276.8 million, with midpoint growth of 11%, also 11% organically.
• Moderate pointNine-month sales increased to $204.903 million from $185.149 million in 2025.
• Moderate pointNine-month operating income increased to $55.869 million from $49.080 million in 2025.

12 minor points

• Minor pointGraft sales grew 20% and shunt sales grew 14% in Q3.
• Minor pointArtegraft sales increased 18% in Q3.
• Minor pointQ3 regional sales increased 18% in EMEA, 9% in the Americas and 5% in Asia Pacific.
• Minor pointCash and short-term securities increased $13.5 million sequentially to approximately $390 million at September 30, 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.LeMaitre will receive a portion of profits on B. Braun-originated sales during the transition.
• Minor point. Forward-looking: it has not happened yet and may not happen.Q4 operating income guidance is $18.8–$20.2 million, with midpoint growth of 4%.
• Minor point. Forward-looking: it has not happened yet and may not happen.Q4 EPS guidance is $0.70–$0.75, with midpoint growth of 7%.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full-year operating income guidance is $74.6–$76.1 million, with midpoint growth of 11%, or 17% adjusted.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full-year EPS guidance is $2.77–$2.82, with midpoint growth of 11%, or 18% adjusted.
• Minor pointNine-month net income increased to $47.753 million from $42.152 million in 2025.
• Minor pointNine-month diluted EPS increased to $2.07 from $1.84 in 2025.
• Minor pointQ3 declared dividends were $0.25 per share, versus $0.20 in Q3 2025.

Negative

• Moderate pointQ3 gross margin fell to 71.7% from 75.3%, although it rose from the adjusted 70.8% baseline.
• Moderate pointQ3 operating expenses rose 21% to $31.0 million, or 18% against the adjusted prior-year baseline.
• Moderate pointQ3 operating income fell 13% to $17.7 million, despite 5% growth against the adjusted prior-year baseline.
• Moderate pointB. Braun asset acquisition cost $19.2 million. 1% of market cap
• Minor pointQ3 diluted EPS fell to $0.65 from $0.75, despite 5% growth against the adjusted prior-year baseline.

3 minor points

• Minor pointQ3 net income decreased to $15.024 million from $17.362 million in 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.Acquired sales transition spans 18–24 months, as B. Braun customer contracts conclude or transfer.
• Minor pointNine-month operating cash flow declined to $53.048 million from $58.094 million in 2025.

News Explained

LeMaitre authorized repurchases of its common stock; the program may be suspended or discontinued at any time and is set to end February 18, 2027, unless extended.

Key Figures

Q3 sales: $68.0mm, +11% (+12% organic) Gross margin: 71.7% (-360 bps; +90 bps adjusted) Diluted EPS: $0.65 (-14%; +5% adjusted) +5 more

Q3 sales

$68.0mm, +11% (+12% organic)

Q3 2026

Gross margin

71.7% (-360 bps; +90 bps adjusted)

Q3 2026

Diluted EPS

$0.65 (-14%; +5% adjusted)

Q3 2026

Full-year sales guidance

$274.8mm-$276.8mm (midpoint $275.8mm; +11%, +11% organic)

2026 guidance

Full-year EPS guidance

$2.77-$2.82 (midpoint $2.80; +11%, +18% adjusted)

2026 guidance

Acquired asset purchase price

$19.2mm

Vascular assets acquired from B. Braun in October

Acquired assets' sales

$9.4mm

2025 sales; all outside North America

Quarterly dividend

$0.25/share

Common stock dividend approved October 27, 2026

Previous Earnings Reports

2 past events · Latest: Aug 04

Same Type 2 events

1. Aug 04

   Q2 earnings

   24h Move

   -25.3%

   Q2 results included $70.4m sales and $0.74 diluted EPS; full-year sales midpoint was $276.3m.

2. Nov 06

   Q3 earnings

   24h Move

   +1.4%

   Q3 results included $61.0mm sales and $0.75 diluted EPS; full-year sales guidance midpoint was $248mm.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-gaap, gaap, convertible senior notes, asp

4 terms

non-gaap financial

"Non-GAAP adjusted figures exclude this benefit."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

gaap financial

"A reconciliation of GAAP to non-GAAP measures is included."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

convertible senior notes financial

"Convertible senior notes, net"

Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.

asp financial

"due to higher ASPs and operational efficiencies."

Average selling price (ASP) is the typical price a company receives for a single unit of a product or service, calculated by dividing total revenue by units sold. Investors watch ASP because it shows whether a company is successfully charging more or less for its offerings — like checking the average price per loaf of bread a bakery sells — which directly affects revenue, profit margins, and the health of future sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q3 2026:

• Sales $68.0mm, +11% (+12% organic) vs. Q3 2025
• Gross margin 71.7% (-360bps, +90 bps vs. adjusted)
• Op. expenses $31.0mm (+21%, +18% vs. adjusted)
• Op. income $17.7mm (-13%, +5% vs. adjusted)
• Op. margin 26%
• EPS $0.65 (-14%, +5% vs. adjusted)
• Cash up $13.5mm sequentially to $390mm at 9/30/2026
  
  

Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units.

Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171.

In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next 18-24 months as B. Braun’s customer contracts conclude or transfer to LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales.

Chairman/CEO George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”

Business Outlook

	Q4 2026 Guidance	Full Year 2026 Guidance
Sales	$69.9mm - $71.9mm (Mid $70.9mm, +10%, +11% org.)	$274.8mm - $276.8mm (Mid $275.8mm, +11%, +11% org.)
Gross Margin	72.1%	72.1%
Op. Income	$18.8mm - $20.2mm (Mid $19.5mm, +4%)	$74.6mm - $76.1mm (Mid $75.4mm, +11%, +17% adj.)
Op. Margin (Mid)	27%	27%
EPS	$0.70 - $0.75 (Mid $0.73, +7%)	$2.77 - $2.82 (Mid $2.80, +11%, +18% adj.)

* The top- and bottom-line impacts of the newly acquired B. Braun products are reflected in this Business Outlook. LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact.
** 2025 results include a Q3 non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP measures is included.

Quarterly Dividend

On October 27, 2026, the Company's Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026.

Share Repurchase Program

On February 19, 2026, the Company's Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as "organic" or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025.  Management believes that viewing growth in these measures excluding those effects provides an alternative and meaningful view of the Company’s profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; competition from other medical device companies and alternative medical technologies; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Contact: 

ir@lemaitre.com

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
			September 30, 2026				December 31, 2025
			(unaudited)
Assets
Current assets:
	Cash and cash equivalents		$	27,493			$	28,244
	Short-term marketable securities			362,228				330,876
	Accounts receivable, net			35,876				33,610
	Inventory and other deferred costs			71,272				70,422
	Prepaid expenses and other current assets			8,642				5,080
Total current assets				505,511				468,232
Property and equipment, net				30,465				26,997
Right-of-use leased assets				18,503				15,762
Goodwill				65,945				65,945
Other intangibles, net				29,295				33,089
Deferred tax assets				746				759
Other assets				5,567				4,906
Total assets			$	656,032			$	615,690
Liabilities and stockholders' equity
Current liabilities:
	Accounts payable		$	4,159			$	3,646
	Accrued expenses			26,686				29,411
	Acquisition-related obligations			583				322
	Lease liabilities - short-term			3,192				2,944
Total current liabilities				34,620				36,323
Convertible senior notes, net				169,317				168,645
Lease liabilities - long-term				16,342				14,003
Deferred tax liabilities				2,167				1,735
Other long-term liabilities				1,455				1,468
Total liabilities				223,901				222,174
Stockholders' equity
	Common stock			245				244
	Additional paid-in capital			238,938				228,407
	Retained earnings			215,324				184,715
	Accumulated other comprehensive loss			(4,460	)			(2,411	)
	Treasury stock			(17,916	)			(17,439	)
Total stockholders' equity				432,131				393,516
Total liabilities and stockholders' equity			$	656,032			$	615,690

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
		For the three months ended								For the nine months ended
		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Net sales		$	67,970			$	61,046			$	204,903			$	185,149
Cost of sales			19,265				15,091				57,038				52,800
Gross profit			48,705				45,955				147,865				132,349
Operating expenses:
	Sales and marketing		14,506				11,923				43,429				41,030
	General and administrative		12,083				10,750				35,239				31,633
	Research and development		4,421				2,970				13,328				10,606
Total operating expenses			31,010				25,643				91,996				83,269
Income from operations			17,695				20,312				55,869				49,080
Other income (expense):
	Investment income		3,365				3,864				10,075				9,747
	Interest expense		(1,304	)			(1,297	)			(3,906	)			(3,886	)
	Other income (loss), net		(82	)			(306	)			(503	)			(57	)
Income before income taxes			19,674				22,573				61,535				54,884
Provision for income taxes			4,650				5,211				13,782				12,732
Net income		$	15,024			$	17,362			$	47,753			$	42,152
Earnings per share of common stock
	Basic	$	0.66			$	0.77			$	2.09			$	1.86
	Diluted	$	0.65			$	0.75			$	2.07			$	1.84
Weighted - average shares outstanding:
	Basic		22,871				22,660				22,844				22,615
	Diluted		23,071				24,392				23,064				22,915
Cash dividends declared per common share		$	0.25			$	0.20			$	0.75			$	0.60

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(amounts in thousands)
(unaudited)
			For the nine months ended
			September 30, 2026				September 30, 2025
Operating activities
Net income			$	47,753			$	42,152
Adjustments to reconcile net income to net cash provided by operating activities
	Depreciation and amortization			8,170				7,813
	Stock-based compensation			6,056				5,730
	Amortization of issuance costs on convertible notes			672				653
	Non-cash investment income			(253	)			-
	Provision for inventory write-downs			2,548				1,893
	Provision for credit losses			675				455
	Foreign currency transaction effect on income			316				(79	)
Changes in operating assets and liabilities:
	Accounts receivables			(3,347	)			(1,403	)
	Inventory and other deferred costs			(3,584	)			(6,805	)
	Prepaid expenses and other assets			(4,244	)			1,639
	Accounts payable and other liabilities			(636	)			5,327
	Accrued interest			(1,078	)			719
Net cash provided by operating activities				53,048				58,094
Investing activities
Purchases of short-term marketable securities				(390,987	)			(43,015	)
Purchases of property and equipment				(7,429	)			(5,006	)
Payments related to acquisitions, net of cash acquired				(194	)			(95	)
Proceeds from short-term marketable securities				358,201				-
Net cash used in investing activities				(40,409	)			(48,116	)
Financing activities
Proceeds from stock option exercises				4,473				4,657
Deferred payments for acquisitions				(95	)			(1,433	)
Payment of withholding taxes in connection with net settlement of equity awards				(477	)			(605	)
Common stock cash dividend paid				(17,144	)			(13,572	)
Net cash used in financing activities				(13,243	)			(10,953	)
Effect of exchange rate changes on cash and cash equivalents				(147	)			859
Net (decrease) increase in cash and cash equivalents				(751	)			(116	)
Cash and cash equivalents at beginning of period				28,244				25,610
Cash and cash equivalents at end of period			$	27,493			$	25,494

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
		For the three months ended												For the nine months ended
		September 30, 2026						September 30, 2025						September 30, 2026						September 30, 2025
		$			%			$			%			$			%			$			%
Net Sales by Geography
	Americas	$	42,713		63	%		$	39,218		64	%		$	127,763		62	%		$	119,496		64	%
	Europe, Middle East and Africa		20,830		31	%			17,631		29	%			63,254		31	%			53,431		29	%
	Asia Pacific		4,427		6	%			4,197		7	%			13,886		7	%			12,222		7	%
Total Net Sales		$	67,970		100	%		$	61,046		100	%		$	204,903		100	%		$	185,149		100	%

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
				For the three months ended								For the nine months ended
				September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Reconciliation between GAAP Net Income and Non-GAAP Adjusted EBITDA
	Net income as reported			$	15,024			$	17,362			$	47,753			$	42,152
	Employee retention tax credit, net				-				(3,380	)			-				(3,380	)
	Interest (income) expense, net				(2,061	)			(2,567	)			(6,169	)			(5,861	)
	Amortization and depreciation expense				2,885				2,612				8,170				7,812
	Provision for income taxes				4,650				5,211				13,782				12,732
	Adjusted EBITDA			$	20,498			$	19,238			$	63,536			$	53,455
	Adjusted EBITDA percentage increase				7	%											19	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP sales growth:
	For the three months ended September 30, 2026
		Net sales as reported		$	67,970
		Impact of currency exchange rate fluctuations			439
		Adjusted net sales						$	68,409
	For the three months ended September 30, 2025
		Net sales as reported		$	61,046
		Adjusted net sales						$	61,046
		Adjusted net sales increase for the three months ended September 30, 2026						$	7,363			12	%
Reconciliation between GAAP and Non-GAAP gross margin growth:
	For the three months ended September 30, 2026
		Gross margin as reported			71.7	%
		Adjusted gross margin							71.7	%
	For the three months ended September 30, 2025
		Gross margin as reported			75.3	%
		Employee Retention Tax Credit impact			-4.5	%
		Adjusted gross margin							70.8	%
		Adjusted gross margin increase for the three months ended September 30, 2026										0.9	%
Reconciliation between GAAP and Non-GAAP operating expense growth:
	For the three months ended September 30, 2026
		Operating expense as reported		$	31,010
		Adjusted operating expense						$	31,010
	For the three months ended September 30, 2025
		Operating expense as reported		$	25,643
		Employee Retention Tax Credit impact			667
		Adjusted operating expense						$	26,310
		Adjusted operating expense increase for the three months ended September 30, 2026						$	4,700			18	%
Reconciliation between GAAP and Non-GAAP operating income growth:
	For the three months ended September 30, 2026
		Operating income as reported		$	17,695
		Adjusted operating income						$	17,695
	For the three months ended September 30, 2025
		Operating income as reported		$	20,312
		Employee Retention Tax Credit impact			(3,380	)
		Adjusted operating income						$	16,932
		Adjusted operating income increase for the three months ended September 30, 2026						$	763			5	%
Reconciliation between GAAP and Non-GAAP earnings per share growth:
	For the three months ended September 30, 2026
		Earnings per share as reported		$	0.65
		Adjusted earnings per share						$	0.65
	For the three months ended September 30, 2025
		Earnings per share as reported		$	0.75
		Employee Retention Tax Credit impact			(0.13	)
		Adjusted earnings per share						$	0.62
		Adjusted earnings per share increase for the three months ended September 30, 2026						$	0.03			5	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the three months ending December 31, 2026
		Net sales per guidance (midpoint)		$	70,900
		Impact of currency exchange rate fluctuations			507
		Adjusted projected net sales						$	71,407
	For the three months ended December 31, 2025
		Net sales as reported		$	64,453
		Adjusted net sales						$	64,453
		Adjusted projected net sales increase for the three months ending December 31, 2026						$	6,954			11	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the year ending December 31, 2026
		Net sales per guidance (midpoint)		$	275,800
		Impact of currency exchange rate fluctuations			(1,433	)
		Adjusted projected net sales						$	274,367
	For the year ended December 31, 2025
		Net sales as reported		$	249,602
		Net impact of divestitures excluding currency			(1,839	)
		Adjusted net sales						$	247,763
		Adjusted projected net sales increase for the year ending December 31, 2026						$	26,604			11	%
Reconciliation between GAAP and Non-GAAP projected operating income growth:
	For the year ending December 31, 2026
		Operating income per guidance (midpoint)		$	75,400
		Projected operating income						$	75,400
	For the year ended December 31, 2025
		Operating income as reported		$	67,912
		Impact of employee retention credit			(3,380	)
		Adjusted operating income						$	64,532
		Adjusted projected operating income increase for the year ending December 31, 2026						$	10,868			17	%
Reconciliation between GAAP and Non-GAAP earnings per share growth:
	For the year ending December 31, 2026
		Earnings per share per guidance (midpoint)		$	2.80
		Projected earnings per share						$	2.80
	For the year ended December 31, 2025
		Earnings per share as reported		$	2.52
		Impact of employee retention credit			(0.14	)
		Adjusted earnings per share						$	2.38
		Adjusted projected earnings per share increase for the year ending December 31, 2026						$	0.42			18	%

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is LeMaitre's full-year 2026 sales and EPS guidance?

LeMaitre forecasts $274.8–$276.8 million in sales and $2.77–$2.82 in EPS for 2026. Both midpoints represent 11% growth; the EPS midpoint represents 18% growth against the adjusted prior-year baseline. The outlook includes the newly acquired B. Braun products.

What did LeMaitre acquire from B. Braun?

LeMaitre acquired certain B. Braun vascular assets for $19.2 million in October. They comprise polyester and silver-coated grafts, valve cutters and vein strippers. The products recorded $9.4 million in 2025 sales, all outside North America.

What are the record and payment dates for LeMaitre's quarterly dividend?

The $0.25-per-share quarterly dividend is payable on December 3, 2026, to common stockholders of record on November 19, 2026. The board approved the dividend on October 27, 2026.

Why do LeMaitre's Q3 2026 adjusted comparisons differ from GAAP comparisons?

The adjusted comparisons exclude the employee retention tax credit benefit received in Q3 2025. That prior-year benefit affects comparisons for gross margin, operating expenses, operating income and EPS. The adjusted measures supplement rather than replace GAAP results.